Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences-Reference-Cited by-同舟云学术

Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

Published:2019-11-12 Issue:12 Volume:8 Page:878-882
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Lippert Jörg¹,Burghaus Rolf¹,Edginton Andrea²,Frechen Sebastian¹,Karlsson Mats³,Kovar Andreas⁴,Lehr Thorsten⁵,Milligan Peter⁶,Nock Valerie⁷,Ramusovic Sergej⁴,Riggs Matthew⁸,Schaller Stephan⁹,Schlender Jan¹,Schmidt Stephan¹⁰,Sevestre Michaël¹¹,Sjögren Erik³⁶,Solodenko Juri¹,Staab Alexander⁷,Teutonico Donato¹²

Affiliation:

1. Clinical Pharmacometrics Bayer AG Wuppertal Germany

2. School of Pharmacy University of Waterloo Waterloo Canada

3. Faculty of Pharmacy Uppsala University Uppsala Sweden

4. Pharmacokinetics, Dynamics and Metabolism Sanofi‐Aventis Frankfurt Germany

5. Clinical Pharmacy Saarland University Saarbrücken Germany

6. Pharmetheus Uppsala Sweden

7. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

8. Metrum Research Group Tariffville Connecticut USA

9. esqLABS GmbH Saterland Germany

10. College of Pharmacy University of Florida Florida Orlando USA

11. Design2Code Inc Waterloo Ontario Canada

12. Pharmacokinetics, Dynamics and Metabolism Sanofi‐Aventis R&D Alfortville France

Funder

Horizon 2020 Framework Programme

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12473

Reference9 articles.

1. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

2. Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK

3. Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation

4. US Food and Drug Administration.Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry. . Accessed October 28 2019.

5. European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. . Accessed October 28 2019.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy;Clinical Pharmacology & Therapeutics;2024-01-24

2. Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling;Clinical Pharmacology & Therapeutics;2024-01-08

3. Leveraging the use of in vitro and computational methods to support the development of enabling oral drug products: An InPharma commentary;European Journal of Pharmaceutical Sciences;2023-09

4. Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults – an AGePOP review;European Journal of Pharmaceutical Sciences;2023-09

5. Mechanistic Modeling of the Drug‐Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy?;The Journal of Clinical Pharmacology;2023-06